What the research found
A fundamental tension exists when combining insulin therapy with GLP-1 medications: insulin signals your body to store energy as fat, while GLP-1 works by suppressing appetite to mobilise stored fat. The major weight-loss trials for semaglutide and tirzepatide (STEP 2 and the tirzepatide diabetes trial) actually excluded people taking insulin, so their headline results don't directly address this scenario.
When researchers did study GLP-1 added to existing insulin therapy, the results showed modest weight loss. Semaglutide added to long-acting insulin produced 3.7–6.4 kg loss depending on dose; tirzepatide added to insulin glargine produced 5.4–8.8 kg loss. Importantly, the insulin-only control groups gained weight. However, only two observational studies have directly compared insulin users to non-users on the same GLP-1 dose—one finding no difference in weight loss, the other finding roughly 2 kg less loss in those who remained on insulin. This is sparse evidence: just over 1,000 patients total, and no randomised trial yet exists.
Why it matters for you
If you're managing type 2 diabetes on insulin while starting a GLP-1, your weight-loss trajectory may be slower than peers not on insulin, and slower than the published trial averages. This doesn't mean the GLP-1 isn't working—it means you're fighting competing hormonal signals. The good news: most people on GLP-1 actually need less insulin than before. Your prescriber should be titrating your basal (long-acting) insulin downward and typically removing mealtime insulin doses as your appetite suppression deepens and blood glucose improves.
Track your insulin doses as a biomarker in MyKine. If they're not dropping within the first month or two, flag this with your clinician—it suggests either underdosing of the GLP-1, inadequate titration of insulin, or an underlying reason (like active infection or stress) driving your glucose higher. The gap between your weight loss and someone else's may partly reflect how much insulin you're still taking, and partly reflect the diabetes itself requiring glucose control that the other person doesn't need.
Caveats
- No randomised controlled trial exists on this specific question; evidence rests on two small observational studies pointing in slightly different directions
- The trials that do exist excluded insulin users, so their weight-loss estimates don't directly apply to your situation
- Add-on studies used diabetes-level dosing, not the higher GLP-1 doses used for weight loss in non-diabetics, so direct comparison is imperfect
- Observational studies can't separate insulin's direct effect from the diabetes severity that necessitated insulin in the first place
- Individual insulin sensitivity and glucose control quality vary widely and weren't reported in detail across these studies